Your browser doesn't support javascript.
loading
Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer.
García, Margarita; Martinez-Villacampa, Mercedes; Santos, Cristina; Navarro, Valentin; Teule, Alex; Losa, Ferran; Pisa, Aleydis; Cambray, Maria; Soler, Gemma; Lema, Laura; Kreisler, Esther; Figueras, Agnes; Juan, Xavier San; Viñals, Francesc; Biondo, Sebastiano; Salazar, Ramon.
Afiliação
  • García M; Clinical Research Unit, Institut Català d'Oncologia, Avinguda Gran Via de l'Hospitalet, 199-203 08907 L'Hospitalet de Llobregat, Barcelona, Spain. mgarciamartin@iconcologia.net.
  • Martinez-Villacampa M; Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. mmvillacampa@iconcologia.net.
  • Santos C; Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. csantos@iconcologia.net.
  • Navarro V; Clinical Research Unit, Institut Català d'Oncologia, Avinguda Gran Via de l'Hospitalet, 199-203 08907 L'Hospitalet de Llobregat, Barcelona, Spain. vnavarro@iconcologia.net.
  • Teule A; Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. ateule@iconcologia.net.
  • Losa F; Department of Medical Oncology, Hospital General de L'Hospitalet, Barcelona, Spain. ferran.losa@sanitatintegral.org.
  • Pisa A; Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. apisa@tauli.cat.
  • Cambray M; Department of Radiotherapy, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. mcambray@iconcologia.net.
  • Soler G; Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. gsoler@iconcologia.net.
  • Lema L; Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. laura.lema@gmail.com.
  • Kreisler E; Department of Surgery, Hospital Universitario de Bellvitge -IDIBELL, L'Hospitalet, Barcelona, Spain. ekreisler@bellvitgehospital.cat.
  • Figueras A; Translational Research Laboratory, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. afigueras@iconcologia.net.
  • Juan XS; Department of Pathology, Hospital Universitario de Bellvitge -IDIBELL, L'Hospitalet, Barcelona, Spain. sanjuan@bellvitgehospital.cat.
  • Viñals F; Translational Research Laboratory, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. fvinyals@iconcologia.net.
  • Biondo S; Department of Surgery, Hospital Universitario de Bellvitge -IDIBELL, L'Hospitalet, Barcelona, Spain. sbiondo@bellvitgehospital.cat.
  • Salazar R; Department of Medical Oncology, Institut Català d'Oncologia-IDIBELL, L'Hospitalet, Barcelona, Spain. ramonsalazar@iconcologia.net.
BMC Cancer ; 15: 59, 2015 Feb 26.
Article em En | MEDLINE | ID: mdl-25886275
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Protocolos de Quimioterapia Combinada Antineoplásica / Quimiorradioterapia Adjuvante / Capecitabina / Bevacizumab Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Retais / Protocolos de Quimioterapia Combinada Antineoplásica / Quimiorradioterapia Adjuvante / Capecitabina / Bevacizumab Tipo de estudo: Prognostic_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article